
Ilya Pharma
Developing local-acting immunotherapies
Novel therapeutic modalities that fight disease by giving local instructions to immune cells, for immune modulation and the WHO critical MDR pathogens.
Novel therapies
Human proteins, produced exactly where they are needed
Live, non-colonising lactic acid bacteria act as local mini-bioreactors, producing biochemically unstable human therapeutic proteins directly in skin and mucosa. The approach is inspired by Nobel laureate Ilya Mechnikov's early work on the many functions of immune cells.
About us
Pipeline
Our programs
Oral formulationPre-IND completed
ILP100-Oral
Colitis in cancer patients receiving ICI therapy
L. reuteri expressing human CXCL12 1a (emilimogene sigulactibac) for local immunomodulation in the gut. Superior efficacy versus marketed benchmarks in preclinical colitis models.

Latest
News
News
13 July 2026Ilya Pharma presenting at Gordon Research Conference - Engineered Microbes for Treatment of Disease, Lewiston Aug 2-7 2026
News
8 June 2026Ilya Pharma represented at BIO International, June 22-25 San Diego
News
24 May 2026Shareholders are invited to Annual General Meeting June 15 at 12-13, Uppsala Business Park
Partner with us